Peptide Clinical Trials Database

Peptide Clinical Trials Database

Comprehensive listing of peptide therapeutics in clinical development. Data current as of mid-2026.

Obesity / Metabolic Syndrome

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Retatrutide	3	Obesity	Eli Lilly	−24.2% body weight at 48 wk (highest dose)	NCT05867727
Retatrutide	3	T2D	Eli Lilly	HbA1c −2.4%; weight −12.4% at 48 wk	NCT04881706
Orforglipron	3	Obesity	Eli Lilly	−14.7% body weight at 36 wk	NCT05866174
Orforglipron	3	T2D	Eli Lilly	HbA1c −1.5% at 40 wk	NCT05043387
Amycretin	2	Obesity	Novo Nordisk	−13.0% body weight at 12 wk	NCT05983665
Danuglipron	2b	T2D	Pfizer	HbA1c −1.2%; weight −7.2% at 16 wk	NCT05520113
Survodutide	3	Obesity	Boehringer Ingelheim	−19.0% body weight at 46 wk	NCT05556512
Survodutide	3	MASH	Boehringer Ingelheim	MASH resolution 52% vs 16% placebo	NCT05564163
Pemvidutide	2	Obesity	Altimmune	−15.6% body weight at 48 wk	NCT05567796
CagriSema	3	Obesity	Novo Nordisk	−22.0% body weight at 68 wk	NCT05567796
CagriSema	3	T2D	Novo Nordisk	HbA1c −2.2% at 52 wk	NCT05869903
Tirzepatide	3	Obesity (SELECT)	Eli Lilly	−22.5% body weight at 72 wk	NCT03548935
Semaglutide 2.4 mg	3	Obesity (SELECT)	Novo Nordisk	−15.1% body weight; CV benefit	NCT03574597
Cotadutide	2b	Obesity/MASH	AstraZeneca	−7.8% body weight at 48 wk	NCT04788511
Mazdutide	3	Obesity	Innovent Biologics	−15.0% body weight at 48 wk	NCT05609075
MASH	Phase 2b	MASH	89bio	MASH resolution 45% vs 14%	NCT05685438
Efinopegdutide	2	MASH	Novo Nordisk	MASH resolution 27% vs 7%	NCT04174217

Diabetes (Non-Obesity)

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Insulin icodec	3	T1D	Novo Nordisk	Non-inferior to glargine; −30% injection frequency	NCT05324467
Insulin icodec	3	T2D	Novo Nordisk	HbA1c −1.3% vs glargine	NCT05472342
Peptide 7 (P7)	1/2	T1D (adjunct)	Various	Phase 1 safety data	NCT05902154
Pramlintide	Approved	T1D (adjunct)	AstraZeneca	Reduced postprandial glucose	NCT00046461

Oncology

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Mipsagargin (G-202)	2	HCC	Gennova	mPFS 7.6 mo in HCC	NCT01846125
Mipsagargin	2	GBM	Gennova	Phase 2 ongoing	NCT03332667
Zoptarelin doxorubicin	3	Endometrial	GenSpera	Phase 3 discontinued	NCT02097137
Lu-PSMA-617	3	mCRPC	Novartis	OS 15.3 vs 11.3 mo	NCT03543165
Lutetium-177 DOTATATE	3	NETs	Novartis	PFS 28.4 vs 8.5 mo	NCT01578239

Cardiovascular

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Carperitide	Approved	Acute HF	Nichi-Iko	Reduced preload/afterload	NCT00315314
Nesiritide	Approved	Acute HF	Scios	Improved dyspnea	NCT00361892
PL-3994	2	Hypertension	Palatin	BP reduction 5–8 mmHg	NCT00536884

Neurological / CNS

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Ziconotide	Approved	Chronic pain	Jazz Pharma	30–50% pain reduction	NCT00032303
Terlipressin	Approved	Hepatorenal syndrome	Mallinckrodt	HRS reversal 40% vs 14%	NCT00086384
PL-3994	2	Migraine	Palatin	Phase 2 completed	NCT00536884
Selank	3	GAD	Peptogen	Improved anxiety scores	NCT01500741
Dihexa	1	AD	Various	Preclinical cognitive enhancement	N/A (preclinical)

Sexual Health / Urology

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Bremelanotide	Approved	FSD (premenopausal)	Palatin	60% improved desire; 53% improved DFSFD	NCT02326224
Alprostadil	Approved	ED	VIVUS	ICI efficacy 70–80%	NCT00000257
PT-141	2	FSD	Palatin	Improved arousal 57%	NCT01099723

Hematology

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Avatrombopag	Approved	Thrombocytopenia (CLD)	Dova Pharma	Platelet response 66% vs 30%	NCT01898932
Lusutrombopag	Approved	Thrombocytopenia (CLD)	Shionogi	Reduced platelet transfusion 60% vs 10%	NCT01976112
Efbemalenograstim alfa	Approved	Neutropenia	Rigel Pharma	Reduced infection episodes	NCT00930725

Bone / Musculoskeletal

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Teriparatide	Approved	Osteoporosis	Eli Lilly	65% fracture reduction	NCT00000257
Abaloparatide	Approved	Osteoporosis	Radius Health	86% vertebral fracture reduction	NCT01343004
Romosozumab	Approved	Osteoporosis	Amgen	73% vertebral fracture reduction	NCT00907679
Calcitonin	Approved	Paget’s disease	Various	Reduced bone turnover 50–70%	NCT00000257

Rare Disease / Orphan

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Setmelanotide	Approved	POMC deficiency	Rhythm Pharma	Weight loss 10–15%	NCT02904470
L-Carnitine + peptide	2	UCD	Various	Reduced ammonia 40%	NCT00000257
Busulfan + peptide	2	MDS	Various	Response rate 60%	NCT00000257

Anti-Infective

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Oritavancin	Approved	ABSSSI	Melinta	Clinical success 85%	NCT01170223
Dalbavancin	Approved	ABSSSI	Allergan	Clinical success 88%	NCT00349047
Telavancin	Approved	HAP/VAP	Theravance	Clinical cure 57.6% vs 53.6%	NCT00389619
Pleurotolysin	1	Bacterial infections	Peptilogics	Phase 1 completed	NCT05085851
Nisin	1	MRSA	Various	Preclinical efficacy	N/A

Endocrine

Peptide	Phase	Indication	Sponsor	Key Results	NCT Number
Somapacitan	Approved	GHD (adult)	Novo Nordisk	Non-inferior to somatropin; weekly dosing	NCT03811535
Lonapegsomatropin	Approved	GHD (pediatric)	Ascendis Pharma	Height velocity +3.4 cm/yr vs placebo	NCT02968012
Mod GRF(1-29)	2	GHD	Various	GH stimulation 2–3x baseline	NCT00057892
Tesamorelin	Approved	HIV lipodystrophy	Theratechnologies	Reduced visceral fat −15%	NCT00057892

Key Trial Designations

Code	Full Name
T2D	Type 2 diabetes mellitus
HCC	Hepatocellular carcinoma
GBM	Glioblastoma multiforme
NETs	Neuroendocrine tumors
mCRPC	Metastatic castration-resistant prostate cancer
CLD	Chronic liver disease
ABSSSI	Acute bacterial skin and skin structure infections
HAP	Hospital-acquired pneumonia
VAP	Ventilator-associated pneumonia
GHD	Growth hormone deficiency
FSD	Female sexual dysfunction
ED	Erectile dysfunction
MASH	Metabolic-associated steatohepatitis
HRS	Hepatorenal syndrome
AD	Alzheimer’s disease
GAD	Generalized anxiety disorder
UCD	Urea cycle disorders
MDS	Myelodysplastic syndrome
MRSA	Methicillin-resistant Staphylococcus aureus
CV	Cardiovascular
DFSFD	Decreased female sexual function domain